Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03542110 · ClinicalTrials.gov registry record · Phase 4
The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial
A Phase 4 study, sponsored by Minneapolis Heart Institute Foundation.
- Terminated
- Registry status
- Phase 4
- Development phase
- 46
- Enrollment target
NCT03542110: Clinical Trial Phase 4 study, sponsored by Minneapolis Heart Institute Foundation.
NCT03542110 is a Phase 4 study that was terminated before completion, run by Minneapolis Heart Institute Foundation. The registered enrollment target is 46 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03542110, a Phase 4 study, was terminated before completion, sponsored by Minneapolis Heart Institute Foundation.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 46 participants
- Enrollment target
Study Summary
This is a phase IV, multi-center, double-blind, randomized, placebo- controlled study evaluating the effect of alirocumab on SVG atherosclerotic disease burden, as assessed by IVUS at baseline and following 78 weeks of treatment in subjects with at least one intermediate SVG lesion receiving optimal statin therapy. Subjects will be randomized 1:1 into 2 treatment groups: alirocumab 150 mg subcutaneously every 2 weeks or placebo subcutaneously every 2 weeks.
Primary Outcome
To evaluate the effect of alirocumab on the change in burden of saphenous vein graft (SVG) atherosclerosis as measured by percent atheroma volume (PAV) in patients with intermediate SVG lesions who are undergoing clinically-indicated coronary angiography and are receiving optimal statin therapy.
Interventions
- DRUG Alirocumab 150 MG/ML subcutaneous injection
- DRUG Matching Placebo subcutaneous injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2018-08-04 |
| Est. Completion | 2020-07-31 |
| Phase | Phase 4 |
Why NCT03542110 stopped before completion
NCT03542110 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 2 interventions - of which Alirocumab 150 MG/ML subcutaneous injection is the first listed.
NCT03542110 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03542110 about?
NCT03542110 is a clinical study titled "The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial". This is a phase IV, multi-center, double-blind, randomized, placebo- controlled study evaluating the effect of alirocumab on SVG atherosclerotic disease burden, as assessed by IVUS at baseline and following 78 weeks of treatment in subjects with at least one intermediate SVG lesion receiving optimal...
What is the current status of trial NCT03542110?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 46 participants. The study started on 2018-08-04. Estimated completion is 2020-07-31.
What interventions are being tested in trial NCT03542110?
The interventions under investigation include: Alirocumab 150 MG/ML subcutaneous injection (DRUG), Matching Placebo subcutaneous injection (DRUG).
Who is sponsoring clinical trial NCT03542110?
This trial is sponsored by Minneapolis Heart Institute Foundation, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03542110's enrollment target sits among peer trials
46 1348th of 2000 higher than 647 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI